Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir

Antiviral Therapy

Volumn 17, Issue 6, 2012, Pages 973-979

  Chen, En Qiang ^a,b   Zhou, Tao You ^a,b   Bai, Lang ^a,b   Wang, Jing Rong ^a,b   Yan, Li Bo ^a,b   Liang, Ling Bo ^a,b   Tang, Hong ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEROCONVERSION; SEROLOGY; SIDE EFFECT;

ADENINE; ADULT; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; NUCLEOSIDES; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; PYRIMIDINONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865730951     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2190     Document Type: Article

References (35)

1. Williams R. Global challenges in liver disease. Hepatology 2006; 44:521-526.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B. J Hepatol 2009; 50:227-242.
3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
4. Jia JD, Yao GB. Achieving ultimate control of hepatitis B infection in China: progress and challenges. J Viral Hepat 2010; 17 Suppl 1:2-3.
5. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. [The guideline of prevention and treatment for chronic hepatitis B (2010 version)]. Zhonghua Gan Zang Bing Za Zhi 2011; 19:13-24. Chinese.
6. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2:263-283.
7. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 2002; 97:1618-1628.
8. Croagh CM, Bell SJ, Locarnini S, Desmond PV. Assessment of chronic hepatitis B: the importance of hepatitis B virus DNA testing. Intern Med J 2012; 42:170-175.
9. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008; 2:147-151.
10. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137:1593-1608.
11. Locarnini S. Transmission of antiviral drug resistant hepatitis B virus: implications for public health and patient management. J Gastroenterol Hepatol 2010; 25:649-651.
12. Lampertico P. Partial virological response to nucleos(t)ide analogues in naive patients with chronic hepatitis B: from guidelines to field practice. J Hepatol 2009; 50:644-647.
13. Carrouée-Durantel S, Durantel D, Werle-Lapostolle B, et al. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. Antivir Ther 2008; 13:381-388.
14. Gallego A, Sheldon J, Garcia-Samaniego J, et al. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat 2008; 15:392-398.
15. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-2455.
16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743-1751.
17. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5:890-897.
18. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588.
19. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136:486-495.
20. Locarnini S, Bowden S. Drug resistance in antiviral therapy. Clin Liver Dis 2010; 14:439-459.
21. Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 2009; 50:674-683.
22. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49 Suppl 5:S174-S184.
23. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005; 25 Suppl 1:9-19.
24. Brunetto MR, Lok AS. New approaches to optimize treatment responses in chronic hepatitis B. Antivir Ther 2010; 15 Suppl 3:61-68.
25. Wang LC, Chen EQ, Cao J, et al. Combination of lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy. J Viral Hepat 2010; 17:178-184.
26. Chen EQ, Zhou TY, Tang H. Combination of telbivudine and adefovir dipivoxil therapy in chronic hepatitis B patients with poor response to adefovir dipivoxil monotherapy. Int J Infect Dis 2010; 14 Suppl 2:S18.
27. Chen EQ, Wang LC, Lei J, Xu L, Tang H. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J 2009; 6:163.
28. Sheng YJ, Liu JY, Tong SW, et al. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J 2011; 8:393.
29. Alcantara FF, Tang H, McLachlan A. Functional characterization of the interferon regulatory element in the enhancer 1 region of the hepatitis B virus genome. Nucleic Acids Res 2002; 30:2068-2075.
30. Westland CE, Yang H, Delaney WE 4th, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 2005; 12:67-73.
31. Wong CR, Trinh HN, Yip B, et al. High rate of complete viral suppression with combination therapy in patients with chronic hepatitis B and prior treatment failure. J Clin Gastroenterol 2011; 45:900-905.
32. Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009; doi: 10.1007/s12072-009-9140-3.
33. McKeage K, Keam SJ. Telbivudine: a review of its use in compensated chronic hepatitis B. Drugs 2010; 70:1857-1883.
34. Hartwell D, Jones J, Harris P, Cooper K. Telbivudine for the treatment of chronic hepatitis B infection. Health Technol Assess 2009; 13 Suppl 3:23-30.
35. But DY, Yuen MF, Fung J, Lai CL. Safety evaluation of telbivudine. Expert Opin Drug Saf 2010; 9:821-829.